"The results are as good as we could have ever hoped for," says the CEO Anders Haegerstrand.
Watch the interview with the CEO Anders Haegerstrand and CMO/CSO Anna Frostegård below (in English):
Annexin Pharmaceuticals is developing the drug candidate ANXV in the eye disease retinal vein occlusion, RVO, and in cancer. The company recently released phase IIa topline results from its study in RVO. Annexin visited BioStock's studio to talk more about the results and plans going forward.